Zolgensma First To Be Subject To New German Data Collection Rules
Pricing And Reimbursement Body Sets Out New Process
Executive Summary
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
You may also be interested in...
Germany To Increase Data Requirements For Pricing Orphan And Other Drugs
A new bill going through the German legislative process could oblige manufacturers of orphan drugs and certain other products to submit real-world data from registries that would impact pricing.
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.